Immunic, Inc.

Healthcare · Biotechnology · United States

Last price 7.51 USD (Oct 30, 2026, 4:00 PM EST) · Market cap 102.47M

Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports

Immunic, Inc., a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical and phase 2 clinical development for patients with relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis. The company also develops IMU-856, which is entering Phase 2 clinical trial, for the restoration of the intestinal barrier function in patien...